The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells
Abstract
PURPOSE: Provenge (Dendreon Corp, Seattle, WA) is an immunotherapy product consisting of autologous dendritic cells loaded ex vivo with a recombinant fusion protein consisting of prostatic acid phosphatase (PAP) linked to granulocyte-macrophage colony-stimulating factor. Sequential phase I and phase II trials were performed to determine the safety and efficacy of Provenge and to assess its capacity to break immune tolerance to the normal tissue antigen PAP. PATIENTS AND METHODS: All patients had hormone-refractory prostate cancer. Dendritic-cell precursors were harvested by leukapheresis in weeks 0, 4, 8, and 24, loaded ex vivo with antigen for 2 days, and then infused intravenously over 30 minutes. Phase I patients received increasing doses of Provenge, and phase II patients received all the Provenge that could be prepared from a leukapheresis product. RESULTS: Patients tolerated treatment well. Fever, the most common adverse event, occurred after 15 infusions (14.7%). All patients developed immune responses to the recombinant fusion protein used to prepare Provenge, and 38% developed immune responses to PAP. Three patients had a more than 50% decline in prostate-specific antigen (PSA) level, and another three patients had 25% to 49% decreases in PSA. The time to disease progression correlated with development of an immune response to PAP and with the dose of dendritic cells received. CONCLUSION: Provenge is a novel immunotherapy agent that is safe and breaks tolerance to the tissue antigen PAP. Preliminary evidence for clinical efficacy warrants further exploration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kugler, A., Stuhler, G., Walden, P., Zöller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Müller, C. A., Becker, V., et al. (2000) · Nature Medicine · doi:10.1038/73193 · Cited by 639
RetractedDendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Functional diversity of helper T lymphocytes
Abbas, A. K., Murphy, K. M., & Sher, A. (1996) · Nature · doi:10.1038/383787a0 · Cited by 4,450
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationPeptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., & Falo, L. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.283 · Cited by 717
Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V, Schwartz, M., & Fossa, S. D. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.607 · Cited by 385
Morse, M. A., Deng, Y., Coleman, D., Hull, S., Kitrell-Fisher, E., Nair, S. K., Schlom, J., Ryback, M. E., & Lyerly, H. K. (1999) · PubMed · Cited by 300
Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Bakkus, M., Bazin, H., Tielemans, F., Leo, O., Urbain, J., & Moser, M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240317 · Cited by 291
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
Eisenberger, M. A., Simon, R., O'Dwyer, P. J., Wittes, R. E., & Friedman, M. A. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.6.827 · Cited by 267
Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.
Small, E. J., & Vogelzang, N. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.382 · Cited by 207
Self-citationOssevoort, M. A., Feltkamp, M. C. W., van Veen, K. J. H., Melief, C. J. M., & Kast, W. M. (1995) · Journal of Immunotherapy · doi:10.1097/00002371-199508000-00002 · Cited by 133
Peshwa, M. V., Shi, J. D., Ruegg, C. L., Laus, R., & van Schooten, W. C. A. (1998) · The Prostate · Cited by 112
Self-citationKundu‐Raychaudhuri, S., Engleman, E. G., Benike, C. J., Shapero, M. H., DUPUIS, M., van Schooten, W. C. A., Eibl, M. M., & Merigan, T. C. (1998) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1998.14.551 · Cited by 108
Genetic Subtypes of HIV Type 1 and HIV Type 2 Strains in Commercial Sex Workers from Bamako, Mali
Peeters, M., Koumare, B., Mulanga, C., Brengues, C., Baby, M., Bougoudogo, F., Ravel, S., Bibollet‐Ruche, F., & Delaporte, É. (1998) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1998.14.51 · Cited by 75
Systemic treatment for prostate cancer
DOWLING, A. J., & Tannock, I. F. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90062-7 · Cited by 44
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Self-citationCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Antigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926
Decisions About Dendritic Cells: Past, Present, and Future
Steinman, R. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100311-102839 · Cited by 1,274
Dendritic cells as therapeutic vaccines against cancer
Banchereau, J., & Palucka, A. K. (2005) · Nature Reviews Immunology · doi:10.1038/nri1592 · Cited by 1,204
Metadata
- Authors
- Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V., & Valone, F. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-12-01
- Volume
- 18
- Issue
- 23
- Pages
- 3894-3903
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2261691410
- Cited by
- 625
- References
- 19
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.